Acute Rejection of Renal Transplant Clinical Trial
Official title:
The Effects of Pre-transplant Dialysis Modality on Post-transplant Events
This is a prospective, multicenter, comparative, parallel-group, observational study. There
will be 2 cohorts according to pre-transplant dialysis modality (hemodialysis or peritoneal
dialysis). In each cohort, subjects will be observed for 12 months. Approximately, 1040
subjects will be enrolled from 8 transplant centers.
Subjects will be enrolled consecutively until the number of subjects in peritoneal dialysis
group has been 260. It will take 2 years. In this period, the number of subject in
hemodialysis group enrolled in this study will be 780. After finishing the observation of
all subjects, to balance clinical and demographic baseline characteristics between the two
groups, subjects will be selected in each cohort with 1:1 matched using propensity score
method. And then primary and secondary endpoints will be compared between two groups.
1. STUDY OBJECTIVES AND ENDPOINTS 1.1. Objectives
The primary objective of this study is:
• To compare the incidence of composite outcomes (delayed graft function, functional delayed
graft function, primary nonfunction, biopsy-proven acute rejection) of pre-transplant
dialysis modality hemodialysis versus peritoneal in recipients of first renal allografts at
1 year posttransplant.
The secondary objectives of this study are:
- To compare the incidence of delayed graft function and functional delayed graft
function of pre-transplant dialysis modality hemodialysis versus peritoneal in
recipients of first renal allografts at 1 year posttransplant;
- To compare the incidence of composite outcomes biopsy-proven acute rejection of
pre-transplant dialysis modality hemodialysis versus peritoneal in recipients of first
renal allografts at 1 year posttransplant;
- To compare the incidence of primary nonfunction of pre-transplant dialysis modality
hemodialysis versus peritoneal in recipients of first renal allografts at 1 year
posttransplant;
- To evaluate the effect of hemodialysis or peritoneal dialysis on graft function in
terms of longitudinal change of eGFR calculated with abbreviated MDRD equation at Weeks
8, 16, 24, 32, 40, and 48 after renal transplant;
- To compare the incidence and the duration of hospitalization after kidney
transplantation of pre-transplant dialysis modality hemodialysis versus peritoneal in
recipients of first renal allografts at 1 year posttransplant;
- To compare the graft loss and subject death rate of pre-transplant dialysis modality
hemodialysis versus peritoneal in recipients of first renal allografts at 1 year
posttransplant.
1.2. Endpoints
Primary endpoint:
- Composite outcome including;
1. Delayed graft function (defined as the need for dialysis in the first week after
transplantation)
2. Functional DGF (defined as the absence of a decrease in serum creatinine level by
a minimum of 10% per day during 3 consecutive days in the first postoperative
week, not including patients in whom acute rejection, calcineurin inhibitor
toxicity, or both, developed within the first week
3. Primary nonfunction (defined as the kidney never achieving function after
transplantation)
4. Biopsy proven acute rejection (defined as scute rejection, confirmed by allograft
biopsy)
Secondary endpoints:
- eGFR (calculated with abbreviated MDRD equation at Weeks 8, 16, 24, 32, 40 and 48 after
renal transplant)
- Hospitalization after kidney transplant (any cause, duration)
- Delayed graft function, functional DGF, Primary nonfunction, biopsy proven acute
rejection (definition of each endpoint is described above)
- Graft loss (return to long-term dialysis)
- Subject death (any cause)
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04665310 -
Evaluation of Anti-rejection Drug, Tacrolimus, in African-Americans With Kidney Transplant
|
Phase 4 | |
Recruiting |
NCT01592253 -
Study to Evaluate Safety and Immunologic Biomarker of Rapamune in Patients With Stable Renal Transplant Recipient
|
N/A | |
Completed |
NCT01496703 -
Reasons for Mycophenolate Mofetil Dose Reduction and Impact on Graft Outcome in Renal Transplant Recipients
|
N/A | |
Completed |
NCT00943228 -
Intensified Dosing of Cellcept (Mycophenolate Mofetil) in Kidney Transplantation
|
Phase 4 | |
Recruiting |
NCT05084768 -
Dd-cfDNA and Treg in Prediction of Kidney Transplant Acute Rejection
|
||
Not yet recruiting |
NCT02558452 -
European Transplant Registry of Senior Renal Transplant Recipients on Advagraf
|
N/A | |
Not yet recruiting |
NCT05799716 -
Treating Donors With Intravenous Immunoglobulin to Reduce Donor-Derived Infections
|
Phase 4 |